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Introduction
The genome of eukaryotic organisms is laid down on a protein-
aceous foundation, the histone octamer, and wrapped around 
it to form the basic unit of chromatin, the nucleosome. This is 
basically how eukaryotes achieve to compact and facilitate the 
organization of the genome within the confines of the nucleus 
and temporally control the access to genetic elements. The 
nucleosome is composed of genomic DNA as well as two cop-
ies of each of the four canonical histones, H2A, H2B, H3 and 
H4. The access to genetic elements is regulated by various enzy-
matic activities including histone posttranslational modifica-
tions, chromatin remodeling and histone exchange by histone 
variants that alter the physical properties of the nucleosome or 
provide alternative sequences for posttranslational modifications 
and regulation.
Histone tails harbour multiple posttranslational modifica-
tions. Historically, it was proposed that these histone modifi-
cations could provide a code, termed appropriately the histone 
code,1 which could dictate biological outcomes through protein-
protein interactions with modification-specific binding proteins, 
broadly called readers. However, recent evidence suggests that 
Correspondence to: Olivier Binda; Email: olivier.binda@newcastle.ac.uk
Submitted: 03/05/13; Revised: 03/24/13; Accepted: 03/26/13
http://dx.doi.org/10.4161/epi.24451
Lysine methylation of histones and non-histone proteins has 
emerged in recent years as a posttranslational modification 
with wide-ranging cellular implications beyond epigenetic 
regulation. The molecular interactions between lysine 
methyltransferases and their substrates appear to be 
regulated by posttranslational modifications surrounding 
the lysine methyl acceptor. Two very interesting examples 
of this cross-talk between methyl-lysine sites are found in 
the SET (Su(var)3–9, Enhancer-of-zeste, Trithorax) domain-
containing lysine methyltransferases SET7 and SETDB1, 
whereby the histone H3 trimethylated on lysine 4 (H3K4me3) 
modification prevents methylation by SETDB1 on H3 lysine 9 
(H3K9) and the histone H3 trimethylated on lysine 9 (H3K9me3) 
modification prevents methylation by SET7 on H3K4. A similar 
cross-talk between posttranslational modifications regulates 
the functions of non-histone proteins such as the tumor 
suppressor p53 and the DNA methyltransferase DNMT1. 
Herein, in cis effects of acetylation, phosphorylation, as well as 
arginine and lysine methylation on lysine methylation events 
will be discussed.
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a modification on the histone tail does not always lead to a pre-
defined biological outcome, but depending on the context may 
even lead to opposite consequences. A notable paradigm involves 
the histone H3 trimethylated on lysine 4 (H3K4me3) mark, which 
is usually associated with transcriptional activity as it is present 
at the transcriptional start site (TSS) of most expressed genes.2 In 
the context of DNA damage responses, H3K4me3 is read by the 
plant homeodomain (PHD) of the inhibitor of growth 2 (ING2) 
tumor suppressor, leading to transcriptional silencing of cell cycle 
genes.3,4 However, in response to genotoxic stress, H3K4me3 can 
also be read by ING4, which, through associated histone acetyl-
transferase activity, stimulates the transcription of cellular adhe-
sion genes.4,5 Thus, the broader term chromatin signaling has 
been gaining popularity.6-8
Lysine methyltransferases (KMTs) are fundamental players 
in the regulation of chromatin signaling. This is emphasized 
by several reports showing that KMTs functional defects can 
lead to cancer,9,10 growth defects,11 neurological disorders,12 and 
other human pathologies. There are currently over 60 KMTs 
predicted in the latest human genome annotation. With the 
exception of DOT1L13,14 and the WRAD complex,15 most KMTs 
harbor a predicted SET domain, which catalyzes the transfer of 
a methyl group from S-adenosylmethionine to the ε-amine on 
the side chain of lysine residue. Although predicted a few years 
ago,16 ten members of the seven β-strand METhylTransferase-
Like (METTL) family were recently characterized as KMTs.17 
Unlike other posttranslational modifications, lysine methylation 
occurs in three different flavors. Specifically, lysines can either be 
unmodified (K), mono (Kme1), di (Kme2) or trimethylated (Kme3). 
These incremental methylation states have the potential to lead 
to diverse biological outcomes through readers. These include 
Ankyrin, Chromo, MBT (Malignant Brain Tumor), PHD, 
PWWP (Proline-Tryptophan-Tryptophan-Proline), Tudor and 
WD40 domains.18 The biological significance of aberrant chro-
matin signaling events is emphasized by the fact that several 
readers have clear links to cancer,19-21 suggesting a central role 
for lysine methylation in maintaining cellular homeostasis and in 
preventing neoplastic diseases.
Specific histone modifications appear to dictate whether 
or not a KMT can further modify its substrate. SET domain-
containing methyltransferases seem to be particularly sensitive 
to the sequence and posttranslational modifications surrounding 
the target lysine site. I will explore within this short review the 
cross-talk between cis lysine methylation sites and other adjacent 
posttranslational modifications within histones H3 (Fig. 1) and 
H4 as well as a few non-histone proteins.
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is inserted in a defined structure within MLL1 SET domain.29 
The bulky and negatively charged phosphate group on H3T3ph 
would hypothetically lead to the repositioning of the threonine 
and likely change the orientation of the neighboring target lysine, 
thereby impairing MLL1 activity on H3K4.29
H3K9me2/3 prevents H3K4me1. The SET7 lysine methyltrans-
ferase monomethylates the histone H3 on lysine 4 (H3K4me1), but 
also modifies non-histone proteins including the tumor suppres-
sors p5330 and pRB,31 the hormone-responsive transcription fac-
tors estrogen receptor α (ERα)32 and androgen receptor (AR),33 
the DNA methyltransferase DNMT1,34 the histone deacetylase 
SIRT1,35 as well as several other non-histone proteins.
Interestingly, SET7 has weaker activity on a H3K9me2 peptide 
relatively to the unmodified H3 peptide.22 In addition, pre-meth-
ylation of H3 on K9 by the methyltransferase SUV39H1, which 
catalyzes the formation of H3K9me3, impaired SET7-dependent 
methylation on H3K4.22 The crystal structure of H3-bound 
SET7 suggests that K9 from H3 is oriented toward the glutamic 
acid 271 (E271) of SET7. H3K9 and SET7E271 are presumably 
making electrostatic interactions.36 Thus, H3K9me3 may affect 
these intermolecular interactions, preventing SET7 from meth-
ylating H3K4.
The mammalian homolog of the Drosophila melanogaster 
Trithorax group (TrxG) protein Ash1, ASH1L is a lysine meth-
yltransferase that methylates histone H3 on possibly several 
sites, but is associated with active transcription.37 Interestingly, 
the methylation activity of ASH1L on H3K4 is impaired by 
H3K9me3.37 However, there is no structural evidence available to 
suggest a possible mechanism that could explain how H3K9me3 
impairs ASH1L-mediated methylation of H3K4.
Biological consequences of H3K4me3 cross-talk. The presence 
of H3R2me2a in the body of genes and TSS prevents the deposi-
tion of H3K4me3 at silenced genes.24 The absence of H3R2me2 and 
the presence of H3R2me2 at the TSS of actively transcribed genes 
facilitate the association of WDR5 with nucleosomes, thereby 
allowing trimethylation of H3K4.27 Upon cell cycle arrest, the 
promoters of several transcriptional regulator genes are enriched 
with the H3R2me2 mark.27 Although global levels of WDR5 
Regulation of H3 Lysine 4 Methylation (H3K4me)
The mixed lineage leukemia (MLL) protein lysine methyltrans-
ferase complex is evolutionarily conserved and mediates the 
methylation of H3K4. Chromosomal translocations of MLL are 
commonly found in leukemias and lead to aberrant expression of 
developmental and hematopoietic genes. Other KMTs that mod-
ify H3K4 include SETD1A and SET7.22 The H3K4me1 modifica-
tion marks enhancers,23 while H3K4me3 surrounds transcriptional 
start sites and positively correlates with gene expression.2
H3R2me2a prevents H3K4me. The asymmetric dimethylation 
of histone H3 arginine 2 (H3R2me2a) by the protein arginine 
methyltransferase PRMT6 precludes the methylation of H3K4 
by the ASH2L/WDR5-containing MLL methyltransferase com-
plex by preventing the WD40 repeat-containing WDR5 subunit 
from interacting with H3.24 The H3R2me2a modification is con-
served in Saccharomyces cerevisiae.25 Interestingly, the H3R2me2a 
mark was shown to associate genome-wide with silenced chro-
matin and to prevent methylation of H3K4 by the Set1 lysine 
methyltransferase.25
H3R2me2s facilitates H3K4me. The recently identified sym-
metrically dimethylated H3R2 (H3R2me2s) histone mark is not 
only found to overlap genome-wide with H3K4me3 in mouse, 
but it is conserved in Xenopus laevis, Drosophila melanogaster 
and Saccharomyces cerevisiae and detected in cis with H3K4me3 
on the same histone tail.26 Interestingly, the methylation of 
H3R2 requires both H3K4me3 as well as H3K4.26 The arginine 
methyltransferases PRMT5 and PRMT7 were recently found to 
catalyze the formation of H3R2me2s.27 Unlike the asymmetrically 
dimethylated form, H3R2me2s facilitates the interaction between 
H3 and the MLL complex subunit WDR5.27 Thus, by enhanc-
ing MLL association with H3, WDR5 presumably facilitates 
H3K4me3 on H3R2me2s modified histones. Summarily, H3R2me2s 
facilitates H3K4me3 and conversely, H3K4me3 facilitates H3R2me2s.
H3T3ph prevents H3K4me3. The trimethylation of H3K4 pre-
vents H3 phosphorylation on tyrosine 3 (H3T3ph) by haspin.28 
Interestingly, the opposite cross-talk effect was also be observed 
by H3T3ph on H3K4 methylation by MLL1.29 Specifically, H3T3 
Figure 1. Cross-talk on histone H3 N-terminus. The amino acid sequence of the histone tail of H3 is annotated to highlight the position of key modified 
residues. Black lines represents published cross-talk events. White lines represent putative cross-talk events. The dashed black line between H3R2 
and H3K4 represents the antagonistic cross-talk between H3R2me2a and H3K4me3. The purple arrows between H3R2 and H3K4 highlight the permissive 
cross-talk between H3R2me2s and H3K4me3.
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alanine mutations could provide additional space to accommo-
date the methyl groups of H3K4me3 into the acidic fold of G9A.
H3R8me potential effect on H3K9me3. The acetylation of 
H3K9 can prevent PRMT5 from methylating H3 arginine 
8 (H3R8),54 thus highlighting a potential cross-talk between 
H3R8me and H3K9me. Interestingly, the structure of G9A reveals 
that H3R8 is surrounded by three aspartic acids (D1074, D1078 
and D1088) and that the amino groups on the side chain of H3R8 
make electrostatic interactions with these three aspartic acid 
residues.53 This acidic fold is shared by H3R8 and H3K9 where 
both H3 basic residues converge. The methylation of H3R8 by 
PRMT5 could undoubtedly sterically impede the proper inser-
tion of H3 tail into the SET domain of G9A and prevent the 
methylation of H3K9.
H3S10ph prevents H3K9me3. Phosphorylation of H3 on serine 
10 (H3S10ph) prevents methylation of H3K9 by G9A55 and by 
SETDB1.43 In addition, H3S10ph severely impairs methylation 
of H3K9 by SUV39H1 in vitro.46 According to H3-bound G9A 
structure,53 the OH group on the side chain of H3S10 makes 
electrostatic interactions with the arginine 1214 of G9A. Thus, 
phosphorylation of H3S10 could destabilize this interaction and 
possibly lead to poor KMT-substrate association and decreased 
H3K9 methylation. However, H3S10ph on already modified 
H3K9me3 does occur and is involved in regulating the associa-
tion of the heterochromatin protein HP1 with H3K9me3.56,57 The 
impaired activity of G9A and SETDB1 on H3S10ph suggests that 
either H3S10 is phosphorylated only after the methylation of 
H3K9 or that another KMT is responsible for the catalysis of 
H3K9me3S10ph.
Biological consequences of H3K9me3 cross-talk. The H3S10ph 
mark prevents subsequent methylation of H3K9, but also pro-
hibits the binding of the HP1 proteins to H3K9me3. Modulation 
of H3S10ph level by inhibiting or silencing the Aurora B kinase 
enhanced the association of HP1 proteins with mitotic chromo-
somes, suggesting a mechanism for the dissociation of HP1 pro-
teins from chromatin during the M phase of the cell cycle.56
Heterochromatin was proposed to be propagated via the 
association of HP1 proteins with H3K9me3, allowing further 
H3K9 methylation by the HP1-associated methyltransferase 
SUV39H1.58 The cross-talk between H3K4me3 and H3K9me3 
could provide a complementary mechanism to prevent the prop-
agation of silenced chromatin states into transcriptionally active 
regions and vice versa.
Regulation of H3 Lysine 27 Methylation (H3K27me)
Although H3K27 surrounding amino acid sequence (ARKSA) is 
very similar to H3K9 (ARKST), only EZH159 and EZH260 were 
reported to catalyze the methylation of H3K27. The monometh-
yled H3K27me1 mark is enriched at actively transcribed promot-
ers whereas the trimethylated H3K27me3 mark is associated with 
silenced promoters.2
H3R26me and H3S28ph potential effect on H3K27me. 
Although the H3-bound EZH2 structure has not been solved 
yet, it is tempting to speculate based on the aforementioned 
cross-talk between H3K4 and H3K9 that either methylation of 
are diminished in growth arrested cells, WDR5 is enriched at 
H3R2me2-marked promoters.27
The H3R2me2s mark enhances the affinity of the RAG2 PHD 
domain for H3K4me3 by 20-fold.26 Thus, the cross-talk between 
H3R2me2 and H3K4me3 possibly controls V(D)J recombination 
events mediated by RAG2 by enhancing the association of RAG2 
at dually modified H3R2me2K4me3 chromatin loci, such as antigen 
receptor genes.
The MLL complex subunit Ash2L stimulates transcription 
that is driven by the TBP-associated factor TAF3 through meth-
ylation of H3K4 and thereby enhancing the interaction between 
H3K4me3 and the PHD domain of TAF3.38 However, upon 
phosphorylation of H3T3 by haspin, Ash2L fails to stimulate 
TAF3-activated transcription.39 In addition, H3T3 phosphoryla-
tion by haspin during mitosis is essential for proper alignment 
of metaphase chromosomes.40 Hypothetically, phosphorylation 
of H3T3 by haspin during mitosis could prevent the deposition 
of H3K4me3 marks and the opening of condensed centromeric 
chromatin. Interestingly, pharmacological inhibition of haspin 
activity induces centrosome amplification, mitotic catastrophe 
and apoptosis.41
Regulation of H3 Lysine 9 Methylation (H3K9me)
First identified as an H3K9-specific methyltransferase in 2002,42 
SETDB1 modifies H3K943 and ING2 in vitro.44 Interestingly, 
SETDB1 catalytic activity is enhanced by an ATPase, mAM, 
which allows SETDB1 to convert H3K9me2 to H3K9me3.45 There 
are several other H3K9-specific KMT, including SUV39H1,46 
SUV39H247 G9A,48 and PRDM2.49 Interestingly, G9A, GLP, 
SETDB1 and SUV39H1 form an enzymatic complex.50 The 
H3K9me2 and H3K9me3 marks are enriched at the transcriptional 
start site of silenced genes, while H3K9me1 is found at transcribed 
promoters.2
H3K4me3 prevents H3K9me3. Interestingly, the euchromatic 
mark H3K4me3 prevents methylation of H3K9 by SETDB1 as 
well as by the other H3K9-specific KMTs G9A and SUV39H1.44 
In vitro experimental approaches showed that H3K4me3 compro-
mised methylation of H3K9 by SETDB1, G9A and SUV39H1.44 
Importantly, depletion of WDR82, an essential subunit of H3K4-
specific KMT complexes,51 led to severe reductions in H3K4me2/3 
levels and concomitant increase in H3K9me3 levels in vivo,44 argu-
ing that methylation on the H3K4 site could inherently preclude 
H3K9 methylation, providing a passive mechanism for the segre-
gation of the euchromatic and heterochromatic marks H3K4me3 
and H3K9me3, respectively. It was independently reported that an 
un-specified methylation state of H3K4 impaired H3K9 meth-
ylation by SUV39H1 in vitro.52
The structure of G9A reveals that histone H3 lysine 4 is bur-
ied in an acidic fold comprising the aspartic acids D1074 and 
D1088,53 suggesting that the aspartic acid residues would confer 
electrostatic interactions with the positively charged H3K4 and 
that methylation of H3K4 could interfere with those interac-
tions. Indeed, G9A activity on H3 is lower on H3K4me3, but the 
D1074A/D1088A G9A mutant has increased activity on H3K4me3 
compared with the unmodified protein.44 Hypothetically, the 
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53BP1 from chromatin at DNA damage breaks, allowing the 
recruitment of BRCA1 and homologous recombination repair.69
H2A and the H2A variant H2AZ. The dual modification 
H2AK5ac K9me1 was recently detected by mass spectrometry.67 
Interestingly, H2AK5 aligns with H2AZK4 and H2AK9 aligns 
with H2AZK7. Both K4 and K7 on H2AZ were recently reported 
to be methylated by the methyltransferase SETD6.72 However, 
acetylation and methylation of H2AZ are mutually exclusive 
modifications.72 Given the similarities between the H2AK5K9 
and H2AZK4K7 sequences, it seems likely that SETD6 could be 
responsible for the reported methylation of H2AK9.
Non-histone Protein Substrates Cross-talk
Tumor suppressor p53. The p53 tumor suppressor protein is 
methylated on at least four lysine residues. SMYD2 mono-meth-
ylates p53 on lysine K370 (p53K370me1),73,74 while SET7 mono-
methylates p53 on lysine K372 (p53K372me1)30 in the regulatory 
domain. The p53K372me1 modification leads to p53-dependent 
transcriptional activation.30 Interestingly, the SET7-mediated 
p53K372me1 modification prevents methylation by SMYD2 on 
K370 and repression of p53 activities.73 However, the SMYD2-
mediated methylation of p53, p53K370me1, does not affect 
SET7 activity on p53.73 The p53-bound SMYD2 structure was 
resolved and highlights several interactions between p53K372 
and SMYD2 SET domain, including an hydrogen bond between 
p53K372 ε-amine group and the carbonyl of SMYD2 valine 
215.74 Therefore suggesting that p53K372me1 could sterically 
hinder the interaction of p53K372 with SMYD2 valine 215 and 
impair the methylation of K370 by SMYD2.74
The tumor suppressor is also dimethylated by the G9A and 
G9A-like KMT GLP on lysine 373 (p53K373me2).75 Interestingly, 
the aliphatic side chain of K373 from p53 is inserted within 
an aromatic cage of the SMYD2 catalytic domain that is lined 
by Y245, Y344, Y370 and Y374. The lysine K373 of p53 inter-
acts directly with the side-chain of SMYD2Y344 through van 
der Waals interactions, whereas its ε-amine of p53K373 forms 
hydrogen bonds OH groups of Y370 and Y374.74 Thus, G9A-
mediated dimethylation of p53, p53K373me2, could hypotheti-
cally increase interactions with SMYD2 aromatic cage, as seen 
with the cation-π interactions-mediated increased affinity 
between ING4
PHD
 and H3K4me3,5 and lead to methylation of 
p53 at K370. This cooperative cross-talk between the two marks 
would be logical as both p53K370me1 and p53K373me2 inactivate 
p53 functions.73,75
Similarly to histones, lysine methylation of p53 not only 
involves cross-talk between the different modifications, but 
also serves as docking sites for readers. Specifically, the recog-
nition of p53K370me2 by 53BP1 has the consequence of activat-
ing p53-dependent transcription.76 The DNA damaging agent 
adriamycine activates a p53-dependent response and induces the 
methylation of p53K372 by SET7.30 Chromatin signaling events 
leading to the methylation of p53 at K372 by SET7 could poten-
tially prevent the modification of K370 by SMYD2 and diminish 
the association between p53 and 53BP1.
H3R26 by PRMT461 or phosphorylation of H3S28 by MSK1/262 
could affect EZH2 association with H3 and its activity on 
H3K27. Mass spectrometric analysis detected the presence of 
H3S28ph on monomethylated and dimethylated H3K27, but not 
on trimethylated H3K27 peptides,63 suggesting that H3K27me3 
and H3S28ph are mutually exclusive modifications and that phos-
phorylation of H3S28 precludes the trimethylation of H3K27.
Regulation of H3 Lysine 79 Methylation (H3K79me)
H3T80ph potential effect on H3K79me. A few years ago the 
H3T80ph modification was detected by mass spectrometric 
analysis,64 opening the possibility that, similarly to the cross-
talk between H3S10ph and H3K9me3, H3T80ph could regulate 
the methylation of H3K79 by DOT1L. The crystal structure of 
the yeast ortholog of DOT1L, Dot1p, highlights an acidic cleft 
that could accommodate the basic charges surrounding H3K79, 
including R72 and R83.65 Thus, the addition of a negatively 
charged phosphate group on H3S80 may affect the substrate-
enzyme interaction. Indeed, the mutation of the acidic cleft of 
Dot1p abolished methyltransferase activity on H3K79.65
Regulation of H4 Lysine 20 Methylation (H4K20me)
H4K16ac and H4K20me are antagonistic marks. Lysine methyla-
tion at H4K20 prevents the acetylation of H4K16 by the acetyl-
transferase p300 in vitro.66 Interestingly, the inverse cross-talk was 
also observed whereby the H4K16ac mark prevents H4K20 meth-
ylation.66 Although the H4K16ac and H4K20me marks are mutu-
ally exclusive, the H4K12ac mark was recently detected along with 
the novel H4K16me1 mark.67 The structure of H4-bound SET868 
reveals that H4K16 is surrounded by alanine 342 (A342), A346 
and histidine 347 (H347), which are found at the carboxy ter-
minal part of SET8 catalytic domain. The side chain of H347 
makes hydrogen bonding with H4 peptide backbone.68 In par-
ticular, the imidazole Nε2 atom of H347 and the backbone car-
bonyl of H4K16 are hydrogen bonding.68 Thus, posttranslational 
modifications of H4K16 could alter these interactions and affect 
SET8 ability to methylate H4K20. Interestingly, an histidine to 
phenylalanine mutation at position 347 (H347F) led to increased 
substrate affinity.68
Biological consequences of H4K20me2 cross-talk. 
Interestingly, the silencing of the histone acetyltransferase TIP60 
decreased H4K16ac levels and induced the stabilization of 53BP1 
association with H4K20me2 at DNA damage sites.69 In addition, 
the inhibition of histone deacetylase activity by Trichostatin A led 
to enhanced H4K16ac levels and concomitant reduction in 53BP1 
association with chromatin at DNA damage foci.69 The interac-
tion of 53BP1 tandem tudor domain (53BP1
TT
) with H4K20me2 
is well-established.70,71 However, the acetylation of lysine 16 on 
H4K20me2 reduced the affinity of 53BP1
TT
 for the mark. The 
acetylated form of H4 likely disrupts electrostatic interactions 
between H4K16 and an acidic patch in 53BP1 tandem tudor 
domain (amino acids E1549, D1550 and E1551).69 The cross-talk 
between H4K16ac and H4K20me2 facilitates the dissociation of 
www.landesbioscience.com Epigenetics 461
Concluding Remark
It is an exciting era for the field of chromatin signaling. With 
each new posttranslational modification being characterized, 
new doors for a potential cross-talk events and chromatin signal-
ing networks open.
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